Brain Scientific Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Subsequent Events

Subsequent Events	12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 19 – SUBSEQUENT EVENTS In accordance with ASC 855 “Subsequent Events,” Company management reviewed all material events through the date this report was issued and the following subsequent events took place. On January 1, 2023, The Company signed an Allonge to the 2019 Note to adjust the outstanding balance to $63,200 and extend the maturity to February 15, 2023. On March 15, 2023 the Company consummated the closing of a private placement offering whereby the Company sold to three accredited investors, for an aggregate purchase price of $200,000 (i) 50% Original Issue Discount Senior Secured Convertible Debentures in the principal amount of $400,000; and (ii) 119,976 warrants to purchase shares of common stock of the Company, par value $0.001 per share.. On March 31, 2023, the Company consummated a second closing of a private placement offering whereby the Company sold to three accredited investors, for an aggregate purchase price of $100,000, (i) 50% Original Issue Discount Senior Secured Convertible Debentures in the principal amount of $200,000; and (ii) 59,988 warrants to purchase shares of common stock of the Company, par value $0.001 per share. The Debentures are due June 10, 2023 unless extended pursuant to the terms of the agreement.

Subsequent Events

12 Months Ended

Dec. 31, 2022

NOTE 19 – SUBSEQUENT EVENTS

In accordance with ASC 855 “Subsequent Events,” Company management reviewed all material events through the date this report was issued and the following subsequent events took place.

On January 1, 2023, The Company signed an Allonge to the 2019 Note to adjust the outstanding balance to $63,200 and extend the maturity to February 15, 2023.

On March 15, 2023 the Company consummated the closing of a private placement offering whereby the Company sold to three accredited investors, for an aggregate purchase price of $200,000 (i) 50% Original Issue Discount Senior Secured Convertible Debentures in the principal amount of $400,000; and (ii) 119,976 warrants to purchase shares of common stock of the Company, par value $0.001 per share.. On March 31, 2023, the Company consummated a second closing of a private placement offering whereby the Company sold to three accredited investors, for an aggregate purchase price of $100,000, (i) 50% Original Issue Discount Senior Secured Convertible Debentures in the principal amount of $200,000; and (ii) 59,988 warrants to purchase shares of common stock of the Company, par value $0.001 per share. The Debentures are due June 10, 2023 unless extended pursuant to the terms of the agreement.